Sylvester Comprehensive Cancer Center

Paediatric therapeutic development workshop on osteosarcoma

The fourth Paediatric Therapeutic Development Workshop focused on osteosarcoma, the most common primary bone cancer in children and young adults. Current treatment of osteosarcoma comprises surgery and chemotherapy. Outcome has shown very little improvement over the last four dec...

Label-free optical biomarker for prostate cancer diagnosis

Reprogramming of cellular metabolism in cancer leads to changes in the activity of metabolic coenzymes NAD(P)H and FAD which can be used as markers of tumorigenesis and metastasis. NAD(P)H and FAD form coupled redox pair and regulator of mitochondrial energy metabolism. Since NAD...

Bone marrow failure syndromes across the age spectrum: diagnostic and therapeutic principles

Bone marrow failure syndromes (BMFS) are a diverse group of disorders that commonly present with pancytopenia and require a structured approach to evaluation. Initial assessment focuses on excluding reversible causes, followed by consideration of inherited and acquired conditions...

Racial and Ethnic Differences in Classic and 11-Oxygenated Androgens in Men

BACKGROUND: Androgen-dependent prostate pathology, including prostate cancer and benign prostatic hyperplasia, differs in prevalence and phenotype across races/ethnicities. Adrenal-derived 11-oxygenated C19 steroids (11-oxyandrogens) are relevant to several androgen-dependent pat...

Emerging Treatments in Bone Tumors: Lessons Learned from the ESMO Annual Meeting

Primary bone sarcomas are rare, heterogeneous malignancies with limited therapeutic options, particularly in metastatic disease where outcomes remain poor. This study synthesizes current literature to evaluate emerging therapeutic strategies and biological determinants of respons...

Bio‐Inspired Biopolymeric Implantable Platform for Localized and Sustained Drug Delivery in Solid Tumor Treatment

ABSTRACT The development of biocompatible and biodegradable drug delivery systems remains a major challenge in cancer therapy, particularly for the localized and sustained release of poorly soluble, unstable, and highly toxic compounds. 7‐Ethyl‐10‐hydroxycamptothecin (SN‐38), the...